MAIA Biotechnology, Inc. (NYSEAMERICAN:MAIA) Director Cristian Luput Buys 22,133 Shares

MAIA Biotechnology, Inc. (NYSEAMERICAN:MAIA) Director Cristian Luput acquired 22,133 shares of the firm’s stock in a transaction on Friday, November 1st. The stock was purchased at an average price of $2.51 per share, with a total value of $55,553.83. Following the acquisition, the director now owns 389,483 shares of the company’s stock, valued at $977,602.33. This represents a 0.00 % increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

MAIA Biotechnology Price Performance

Shares of MAIA Biotechnology stock opened at $2.88 on Tuesday. MAIA Biotechnology, Inc. has a 1 year low of $0.82 and a 1 year high of $5.99. The stock has a market capitalization of $68.86 million, a P/E ratio of -1.77 and a beta of 0.32.

MAIA Biotechnology (NYSEAMERICAN:MAIA) last released its earnings results on Friday, August 9th. The company reported ($0.17) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.33) by $0.16. Equities research analysts expect that MAIA Biotechnology, Inc. will post -1.25 earnings per share for the current fiscal year.

Hedge Funds Weigh In On MAIA Biotechnology

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Virtu Financial LLC purchased a new stake in shares of MAIA Biotechnology in the 1st quarter worth $71,000. Ground Swell Capital LLC purchased a new stake in MAIA Biotechnology in the second quarter worth about $56,000. Finally, Mather Group LLC. raised its stake in shares of MAIA Biotechnology by 50,150.0% in the second quarter. Mather Group LLC. now owns 12,060 shares of the company’s stock worth $41,000 after buying an additional 12,036 shares during the period. Institutional investors own 5.65% of the company’s stock.

About MAIA Biotechnology

MAIA Biotechnology, Inc, a clinical stage biotechnology company, engages in the discovery, development, and commercialization of therapies targeting cancer. The company's lead product candidate is THIO, a telomere-targeting agent that is in Phase II clinical study to evaluate its activity in patients with non-small cell lung cancer.